Martin Voss, MD Memorial Sloan Kettering discusses Integrated Biomarker Analysis for 412 RCC patients Treated on the Phase 3 COMPARZ Trial at the 2017 Kidney Cancer Association symposium in Miami, FL.
Integrated Biomarker Analysis for 412 RCC patients Treated on the Phase 3 COMPARZ Trial
